Investors are closely monitoring CorMedix Inc. (CRMD) following notable activity in the options market, particularly the May 15, 2026 $3 Call, which exhibits some of the highest implied volatility among equity options today. This spike in volatility indicates market expectations for significant fluctuations in CorMedix’s stock, potentially linked to upcoming events.
As of now, CorMedix holds a Zacks Rank of #4 (Sell) in the Medical – Biomedical and Genetics sector, which places it in the bottom 40% of its industry. Over the past month, analysts have downgraded their earnings estimates for the current quarter from 74 cents per share to 46 cents, reflecting a cautious outlook.
